HTGC supply chain intelligence for Hercules Capital, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Hercules Capital, Inc. (HTGC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALEC | Alector, Inc. | 72% | Reciprocal relationship from ALEC graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ALEC graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ALEC g… |
| ALT | Altimmune, Inc. | 72% | Reciprocal relationship from ALT graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ALT graph: h expected cash receipts from our equity transactions and research and develop… |
| ATAI | AtaiBeckley Inc. | 72% | Reciprocal relationship from ATAI graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ATAI graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ATAI g… |
| BCYC | Bicycle Therapeutics plc | 72% | Reciprocal relationship from BCYC graph: arch and development of our product candidates and preclinical programs, raising capital and providing general and administrative support for our operations. … |
| CMPS | COMPASS Pathways plc | 72% | Reciprocal relationship from CMPS graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from CMPS graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from CMPS g… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from DYN graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from DYN grap… |
| ENGN | enGene Therapeutics Inc. | 72% | Reciprocal relationship from ENGN graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ENGN graph: months ended January 31, 2025 to $8.9 million for the three months ended Jan… |
| HRTX | Heron Therapeutics, Inc. | 72% | Reciprocal relationship from HRTX graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from HRTX g… |
| IRON | Disc Medicine, Inc. | 72% | Reciprocal relationship from IRON graph: the agreement, the Company received an upfront payment of $ 0.2 million with additional consideration receivable upon the achievement of certain clinical, reg… |
| KURA | Kura Oncology, Inc. | 72% | Reciprocal relationship from KURA graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from KURA graph: cial to patients who are often elderly and on several concomitant medication… |
| LGNZZ | LGNZZ | 72% | Reciprocal relationship from LGNZZ graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from LGNZZ graph: rketed in India for breast cancer. Zydus Cadila uses the Selexis technolog… |
| MAZE | Maze Therapeutics, Inc. | 72% | Reciprocal relationship from MAZE graph: ment of our Maze Compass platform, or our Compass platform, planned preclinical studies, IND filings and clinical trials for future therapeutic candidates. We… |
| MDGL | Madrigal Pharmaceuticals, Inc. | 72% | Reciprocal relationship from MDGL graph: h and development is very expensive, time-consuming and difficult to design and implement and involves uncertain outcomes. Furthermore, the results of preclin… |
| MEOBF | MEOBF | 72% | Reciprocal relationship from MEOBF graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from MEOBF graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from MEOB… |
| MLTX | MoonLake Immunotherapeutics | 72% | Reciprocal relationship from MLTX graph: e cash, cash equivalents, and short-term marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements to the e… |
| NRDY | Nerdy Inc. | 72% | Reciprocal relationship from NRDY graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from NRDY graph: d design teams who are responsible for developing new and improving existing… |
| OBIO | Orchestra BioMed Holdings, Inc. | 72% | Reciprocal relationship from OBIO graph: ares”), at an exercise price equal to $ 3.67 per share. The exercise price of the Ligand Warrants and the number of Ligand Warrant Shares issuable upon exerci… |
| PHAT | Phathom Pharmaceuticals, Inc. | 72% | Reciprocal relationship from PHAT graph: 50.0 percent if such prepayment is a result of a change in control and (y) upon any refinancing by Hercules such prepayment charge shall be waived in full; an… |
| PHGE | BiomX Inc. | 72% | Reciprocal relationship from PHGE graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from PHGE graph: SPA, we agreed to issue and sell, in a private placement transaction, an agg… |
| QURE | uniQure N.V. | 72% | Reciprocal relationship from QURE graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from QURE graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from QURE g… |
| RCUS | Arcus Biosciences, Inc. | 72% | Reciprocal relationship from RCUS graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from RCUS graph: non-public information and for complying with our disclosure obligations und… |
| REPL | Replimune Group, Inc. | 72% | Reciprocal relationship from REPL graph: rkets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. A weak or… |
| SENS | Senseonics Holdings, Inc. | 72% | Reciprocal relationship from SENS graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from SENS graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from SENS g… |
| SGHT | Sight Sciences, Inc. | 72% | Reciprocal relationship from SGHT graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from SGHT graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from SGHT g… |
| SVRA | Savara Inc. | 72% | Reciprocal relationship from SVRA graph: we may establish; • the number of clinical and nonclinical studies necessary to demonstrate acceptable evidence of the safety and efficacy of our product cand… |
| TGTX | TG Therapeutics, Inc. | 72% | Reciprocal relationship from TGTX graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from TGTX g… |
| VRDN | Viridian Therapeutics, Inc. | 72% | Reciprocal relationship from VRDN graph: Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q, we may require significant additional capital earlier than we currently expect under our presen… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ENGN | enGene Therapeutics Inc. | 92% | Reciprocal relationship from ENGN graph: the Borrower, Hercules Capital, Inc., as agent and lender ("Hercules") and the several banks and other financial institutions or entities (with Hercules, the … |
| LXRX | Lexicon Pharmaceuticals, Inc. | 92% | Reciprocal relationship from LXRX graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from LXRX graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from LXRX g… |
| CMPS | COMPASS Pathways plc | 90% | Reciprocal relationship from CMPS graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from CMPS graph: The Amended Loan Agreement provides for five tranches of term loans in an ag… |
| REPL | Replimune Group, Inc. | 90% | Reciprocal relationship from REPL graph: in significant future amortization expense or intangible asset impairment charges. Moreover, we may not be able to locate suitable acquisition opportunities a… |
| SVRA | Savara Inc. | 90% | Reciprocal relationship from SVRA graph: The First Amendment reset the timing and conditions to the Company’s ability to draw up to $75 million of additional term loans under the Loan Agreement, subj… |
| ALEC | Alector, Inc. | 72% | Reciprocal relationship from ALEC graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ALEC graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ALEC g… |
| ALT | Altimmune, Inc. | 72% | Reciprocal relationship from ALT graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ALT graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from ALT grap… |
| CYTOF | Altamira Therapeutics Ltd. | 72% | Reciprocal relationship from CYTOF graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from CYTOF graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from CYTO… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from DYN graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from DYN grap… |
| LGNZZ | LGNZZ | 72% | Reciprocal relationship from LGNZZ graph: rketed in India for breast cancer. Zydus Cadila uses the Selexis technology platform for Vivitra. We are entitled to earn royalties on sales by Zydus Cadila … |
| MEOBF | MEOBF | 72% | Reciprocal relationship from MEOBF graph: . (vi) Use of estimates The preparation of these consolidated financial statements requires the Group to make estimates and judgments that affect the reporte… |
| PHAT | Phathom Pharmaceuticals, Inc. | 72% | Reciprocal relationship from PHAT graph: te vonoprazan in the future. We may expend our limited resources to pursue a particular indication or formulation for vonoprazan and fail to capitalize on pro… |
| QURE | uniQure N.V. | 72% | Reciprocal relationship from QURE graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from QURE graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from QURE g… |
| RCUS | Arcus Biosciences, Inc. | 72% | Reciprocal relationship from RCUS graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from RCUS g… |
| SENS | Senseonics Holdings, Inc. | 72% | Reciprocal relationship from SENS graph: ing our products or those of our competitors; ● Ascensia’s ability to increase sales of Eversense and to commercialize and sell our future products, and the n… |
| SGHT | Sight Sciences, Inc. | 72% | Reciprocal relationship from SGHT graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from SGHT graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from SGHT g… |
| VRDN | Viridian Therapeutics, Inc. | 72% | Reciprocal relationship from VRDN graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from VRDN g… |
| XYF | X Financial | 72% | Reciprocal relationship from XYF graph: Reciprocal relationship from HTGC graph: om the SEC that permits us to issue stock options and restricted stock to non-employee directors and restricted stock … |
| XYF | X Financial | 72% | om the SEC that permits us to issue stock options and restricted stock to non-employee directors and restricted stock and restricted stock units to certain of our employees, executive officers, and d… |
| REGULATED-INVESTMENT-COMPANY | REGULATED-INVESTMENT-COMPANY | 62% | e portfolio companies. The value of our securities could also be reduced from an increase in market interest rates as rates available to investors could make an investment in our securities less attr… |
| SUMITOMO-MITSUI-BANKING-CORPORATION | SUMITOMO-MITSUI-BANKING-CORPORATION | 62% | e portfolio companies. The value of our securities could also be reduced from an increase in market interest rates as rates available to investors could make an investment in our securities less attr… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| HTGC-DEBT | Debt stack $2.6B | 90% | Market cache reports total debt of $2.6B. |
| HTGC-DEBT-10101 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2022-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ENLT | Enlight Renewable Energy Ltd | 100.00 | 2 | |
| BGC | BGC Group, Inc. | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 1 | ['supplier'] |
| BSX | Boston Scientific Corporation | 100.00 | 2 | |
| BRBI | BRBI BR Partners S.A. | 100.00 | 2 | |
| CANG | Cango Inc. | 100.00 | 2 | |
| ARMP | Armata Pharmaceuticals, Inc. | 100.00 | 2 | |
| FENG | Phoenix New Media Limited | 100.00 | 2 | |
| BLNE | Beeline Holdings, Inc. | 100.00 | 2 | |
| CIB | Grupo Cibest S.A. | 100.00 | 2 | |
| AMBR | Amber International Holding Limited | 100.00 | 2 | |
| BTDR | Bitdeer Technologies Group | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| BLSH | Bullish | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 1 | ['customer'] |
| GANX | Gain Therapeutics, Inc. | 100.00 | 2 | |
| MEOBF | MESOBLAST LTD | 100.00 | 1 | ['customer', 'supplier'] |